Amanda H Klein1, Husam K Mohammad, Rabiah Ali, Brad Peper, Steven P Wilson, Srinivasa N Raja, Matthias Ringkamp, Sarah Sweitzer. 1. From the Departments of Neurosurgery (A.H.K., M.R.) and Anesthesiology and Critical Care Medicine (S.R.), Johns Hopkins University School of Medicine, Baltimore, Maryland; and Department of Pharmacology, Physiology, Neuroscience, School of Medicine, University of South Carolina, Columbia, South Carolina (H.K.M., R.A., B.P., S.P.W., S.S.). Current positions: Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota College of Pharmacy, Duluth, Minnesota (A.H.K.); and College of Health and Human Services, Concordia University, Portland, Oregon (S.S.).
Abstract
BACKGROUND: The current study used recombinant herpes simplex virus type I to increase expression of µ-opiate receptors and the opioid ligand preproenkephalin in peripheral nerve fibers in a mouse model of neuropathic pain. It was predicted that viral vector delivery of a combination of genes encoding the µ-opioid receptor and preproenkephalin would attenuate neuropathic pain and enhance opioid analgesia. The behavioral effects would be paralleled by changes in response properties of primary afferent neurons. METHODS: Recombinant herpes simplex virus type 1 containing cDNA sequences of the µ-opioid receptor, human preproenkephalin, a combination, or Escherichia coli lacZ gene marker (as a control) was used to investigate the role of peripheral opioids in neuropathic pain behaviors. RESULTS: Inoculation with the µ-opioid receptor viral vector (n = 13) reversed mechanical allodynia and thermal hyperalgesia and produced leftward shifts in loperamide (ED50 = 0.6 ± 0.2 mg/kg vs. ED50 = 0.9 ± 0.2 mg/kg for control group, n = 8, means ± SD) and morphine dose-response curves (ED50 = 0.3 ± 0.5 mg/kg vs. ED50 = 1.1 ± 0.1 mg/kg for control group). In µ-opioid receptor viral vector inoculated C-fibers, heat-evoked responses (n = 12) and ongoing spontaneous activity (n = 18) were decreased after morphine application. Inoculation with both µ-opioid receptor and preproenkephalin viral vectors did not alter mechanical and thermal responses. CONCLUSIONS: Increasing primary afferent expression of opioid receptors can decrease neuropathic pain-associated behaviors and increase systemic opioid analgesia through inhibition of peripheral afferent fiber activity.
BACKGROUND: The current study used recombinant herpes simplex virus type I to increase expression of µ-opiate receptors and the opioid ligand preproenkephalin in peripheral nerve fibers in a mouse model of neuropathic pain. It was predicted that viral vector delivery of a combination of genes encoding the µ-opioid receptor and preproenkephalin would attenuate neuropathic pain and enhance opioid analgesia. The behavioral effects would be paralleled by changes in response properties of primary afferent neurons. METHODS: Recombinant herpes simplex virus type 1 containing cDNA sequences of the µ-opioid receptor, humanpreproenkephalin, a combination, orEscherichia coli lacZ gene marker (as a control) was used to investigate the role of peripheral opioids in neuropathic pain behaviors. RESULTS: Inoculation with the µ-opioid receptor viral vector (n = 13) reversed mechanical allodynia and thermal hyperalgesia and produced leftward shifts in loperamide (ED50 = 0.6 ± 0.2 mg/kg vs. ED50 = 0.9 ± 0.2 mg/kg for control group, n = 8, means ± SD) and morphine dose-response curves (ED50 = 0.3 ± 0.5 mg/kg vs. ED50 = 1.1 ± 0.1 mg/kg for control group). In µ-opioid receptor viral vector inoculated C-fibers, heat-evoked responses (n = 12) and ongoing spontaneous activity (n = 18) were decreased after morphine application. Inoculation with both µ-opioid receptor and preproenkephalin viral vectors did not alter mechanical and thermal responses. CONCLUSIONS: Increasing primary afferent expression of opioid receptors can decrease neuropathic pain-associated behaviors and increase systemic opioid analgesia through inhibition of peripheral afferent fiber activity.
Authors: James R Goss; Cara F Harley; Marina Mata; Mark E O'Malley; William F Goins; XiaoPing Hu; Joseph C Glorioso; David J Fink Journal: Ann Neurol Date: 2002-11 Impact factor: 10.422
Authors: John R Lever; Emily A Fergason-Cantrell; Terry L Carmack; Lisa D Watkinson; Fabio Gallazzi Journal: Nucl Med Biol Date: 2019-03-07 Impact factor: 2.408
Authors: Susanna Fürst; Zoltán S Zádori; Ferenc Zádor; Kornél Király; Mihály Balogh; Szilvia B László; Barbara Hutka; Amir Mohammadzadeh; Chiara Calabrese; Anna Rita Galambos; Pál Riba; Patrizia Romualdi; Sándor Benyhe; Júlia Timár; Helmut Schmidhammer; Mariana Spetea; Mahmoud Al-Khrasani Journal: Molecules Date: 2020-05-26 Impact factor: 4.411